Innovation

More Topics
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blastEyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

BioXconomy presents the Asia biopharma and healthcare dealmaking and financing news for the week ending 8 November.

byRichard Daverman
Nov 18, 2024
|
1 Min Read
coloured pencils
Innovation
Nonprofit looks to bring tomorrow’s science into today’s classroomsNonprofit looks to bring tomorrow’s science into today’s classrooms
byMillie Nelson
Nov 11, 2024
1 Min Read
thumbnail
Seed Funding
Europe’s adversity to risk is why the US is ahead, say expertsEurope’s adversity to risk is why the US is ahead
byMillie Nelson
Nov 5, 2024
1 Min Read
Money
Investment
Eyes on Asia: Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScriptEyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
byRichard Daverman
Nov 5, 2024
1 Min Read
Reverse arrow
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchangeEddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
byRichard Daverman
Oct 31, 2024
1 Min Read
Asian currency
Innovation
Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubatorAstellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
byRichard Daverman
Oct 21, 2024
1 Min Read
Eli Lilly logo
Innovation
From east to west: Lilly plans incubators in China and UK
From east to west: Lilly plans incubators in China and UK
Oct 18, 2024
|
1 Min Read
byMillie Nelson, Richard Daverman
Green leaf with sustainability symbol
Business Strategy
The sustainability series: Reflect, rethink, and reform
The sustainability series: Reflect, rethink, and reform
Oct 11, 2024
|
1 Min Read
byMillie Nelson
Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Oct 1, 2024
|
1 Min Read
byMillie Nelson
Hubs
Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?
News from Sanofi, Bayer, AZ plus the return of VC?
Sep 29, 2024
|
1 Min Read
byRichard Daverman
Hubs
Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Sep 23, 2024
|
1 Min Read
byRichard Daverman
photo of a sunrise over solar panels/building
Innovation
Inside five innovative research companies driving progress in oncology and neurology
Driving progress in oncology and neurology
Sep 21, 2024
|
1 Min Read
Chinese flag — Photo
Investment
China biopharma faces a pause; how bad is it?
China biopharma mid-2023 market summary
Sep 21, 2024
|
1 Min Read
byRichard Daverman
Illustration, Science word. Business concept for Study of physical world structure behavior Experimental research — Illustration
Innovation
European drug discovery and development players showcase their science at BIO-Europe 2023
European drug discovery and development players showcase their science
Sep 21, 2024
|
1 Min Read
Plenary at BIO-Europe in Munich
Investment
How industry trends are evolving biotech innovation in 2023
2023 industry trends that helped evolve biotech innovation
Sep 21, 2024
|
1 Min Read
three member panel on stage
Innovation
‘Data matters most’ in biotech, and AI is here to help
‘Data matters most’ in biotech, and AI is here to help
Sep 21, 2024
|
1 Min Read
lab testing with vials closeup
Investment
Early 2024 review of biotech funding and innovation
Early 2024 review of biotech investment and innovation
Sep 20, 2024
|
1 Min Read
photo of panel at BIO Europe Spring 2024
Partnering
Moving from eminence-based to evidence-based healthcare
Moving from eminence-based to evidence-based healthcare
Sep 19, 2024
|
1 Min Read
Investment
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Sep 18, 2024
|
1 Min Read
byRichard Daverman
Partnering
Top five Asia biopharma deals: August 2024
Asia biopharma deals: August 2024
Sep 15, 2024
|
1 Min Read
byRichard Daverman
Partnering
Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA march
Eyes on Asia: News from EpimAb, TargetRx, Hygieai
Sep 7, 2024
|
1 Min Read
byRichard Daverman
Innovation
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Sep 1, 2024
|
1 Min Read
byRichard Daverman
Investment
Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun
Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun
Aug 25, 2024
|
1 Min Read
byRichard Daverman
Abu Dhabi Global Healthcare Week
Innovation
From healthcare to health: 'No country can do this alone,' say experts in UAE
'No country can do this alone,' say experts in UAE
May 14, 2024
|
1 Min Read
byMillie Nelson
Mounajro
Innovation
GLP-1 boom causing pharma players FOMO
GLP-1 boom causing pharma players FOMO
Mar 25, 2024
|
1 Min Read
byMillie Nelson
Innovation
GSK, Novartis, Calliditas among winners at LSX Awards
GSK, Novartis, Calliditas among winners at LSX Awards
Nov 16, 2023
|
1 Min Read
byMillie Nelson
Clinical Trials Word Cloud illustration
Innovation
Clinical trial innovation at BIO-Europe Spring 2023
Clinical trial innovation at BIO-Europe Spring 2023
Sep 21, 2023
|
1 Min Read

News from APAC

Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blastEyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
byRichard Daverman
Nov 18, 2024
5 Min Read
Money
Investment
Eyes on Asia: Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScriptEyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
byRichard Daverman
Nov 5, 2024
3 Min Read
Reverse arrow
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchangeEddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
byRichard Daverman
Oct 31, 2024
3 Min Read

Recommended

Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Plenary at BIO-Europe in Munich
Investment
How industry trends are evolving biotech innovation in 2023
2023 industry trends that helped evolve biotech innovation
three member panel on stage
Innovation
‘Data matters most’ in biotech, and AI is here to help
‘Data matters most’ in biotech, and AI is here to help
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated